The Pfizer logo at the drugmaker’s headquarters in New York ,
KYIV. UkraineGate . 7. August . 2022 | World News .
US drugmaker Pfizer is close to a deal to buy Global Blood Therapeutics, maker of a recently approved sickle cell disease drug, for $5 billion. This is reported by the Wall Street Journal.
Details
Pfizer, one of the leading makers of Covid-19 vaccines, hopes to conclude talks with GBT within days, the newspaper said on Friday, citing people close to the talks.
The GBT sickle cell therapy, sold under the name “Oxbryta,” was approved for children older than 12 in 2019, but won federal approval in December for children ages four to 11.
At the same time, sales of “Oxbryta” helped the laboratory achieve a turnover of 55 million US dollars (and increased by 41%), while the net loss of the company amounted to 81.4 million dollars.
For its part, Pfizer’s revenue rose 47 percent to a record $27.74 billion in the second quarter, thanks to sales of its Covid vaccine and pills.
Global Blood Therapeutics, based in San Francisco, California.
Source: Ukrgate
